All In Biotech

Drug Trial Radar · NCT02654587

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors

Last checked: Nov 19, 2026Latest source record: Feb 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 219 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

219

Actual

Start

Feb 12, 2016

Primary completion

Jan 15, 2021

Study completion Jan 15, 2021

Sponsor

Lead sponsor
OSE ImmunotherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 13, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this clinical trial was to determine if the therapeutic cancer vaccine OSE2101 (TEDOPI) was more effective than standard chemotherapy (docetaxel or pemetrexed) in treating HLA-A2 positive patients with metastatic NSCLC who progressed after sequential or concurrent chemotherapy and immune checkpoint inhibitor given in first or second-line treatment. The main questions were to compare the survival, the tolerance to treatment and the quality of life of patients between the two arms of treatment (OSE2101 versus standard chemotherapy)

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • OSE2101Biological

  • DocetaxelDrug

  • PemetrexedDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Approx. 24 months

Locations

78 sites in 10 countries. Site status is shown where the registry gives one.

  • East Valley Hematology and Oncology medical Group

    Burbank, California

  • Georgetown University Hospital

    Washington D.C., District of Columbia

  • BRCR Medical Center, Inc

    Boca Raton, Florida

  • Pontchartrain Cancer Center

    Covington, Louisiana

  • Meyer Cancer Center, Weill Cornell Medecine

    New York, New York

  • Gabrail Cancer Center Research

    Canton, Ohio

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Robert W. Franz Cancer Center

    Portland, Oregon

  • Gesinger Medical Center

    Danville, Pennsylvania

  • Millenium Oncology

    Houston, Texas

  • Nemocnice Jihlava, Onkologické oddelení

    Jihlava, Czechia

  • Všeobecná Fakultní nemocnice

    Prague, Czechia

  • Institut Saint Catherine

    Avignon, France

  • Hôpital Avicenne

    Bobigny, France

  • Institut Bergonié

    Bordeaux, France

  • CHGU Morvan - Brest

    Brest, France

  • Hôpital Louis Pradel

    Bron, France

  • Centre Hospitalier de Cholet

    Cholet, France

  • Hôpital intercommunal de Créteil

    Créteil, France

  • CHU Grenoble

    Grenoble, France

  • Clinique Victor Hugo

    Le Mans, France

  • Centre Hospitalier du Mans

    Le Mans, France

  • Hopital Albert Calmette

    Lille, France

  • Paoli-Calmettes Institute

    Marseille, France

  • CHU Montpellier

    Montpellier, France

  • Hôpital Emile Muller

    Mulhouse, France

  • Centre Catherine de Sienne

    Nantes, France

  • Hôpital Saint-Louis

    Paris, France

  • Hôpital Bichat - Claude-Bernard

    Paris, France

  • Hôpital Tenon

    Paris, France

  • Hôpital d'Instruction des Armées Bégin

    Saint-Mandé, France

  • CHU de Strasbourg - Hôpital Civil

    Strasbourg, France

  • Hôpital Larrey - CHU de Toulouse

    Toulouse, France

  • Centre Hospitalier Régional Universitaire de Tours

    Tours, France

  • Centre Hospitalier Troyes

    Troyes, France

  • Institut Gustave Roussy (IGR)

    Villejuif, France

  • Krankenhaus Mehrheit - Kliniken der Stadt Köln - Lungenklinik

    Cologne, Germany

  • Klinik für Innere Medizin II Hospital Martha-Maria Halle-Dölau gGmbH

    Halle, Germany

  • Universitätsklinikum Tübingen Medizinische Klinik II

    Tübingen, Germany

  • Klinik für Innere Medizin II Universitätsklinikum Ulm

    Ulm, Germany

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.